Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Veriheal

MARCH 18, 2021

They needed a model for Alzheimer’s disease in order to effectively review cannabidiol (CBD) as a potential treatment. Unfortunately, both of these conditions result in cognitive decline and suffer from a lack of effective treatment. Why Aging Cats? What Did The Study Find?

CBD 109

CBD Research and Development Pets Treatment 109

Veriheal

JUNE 29, 2022

Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. Exploring Psilocybin and Treatment-Resistant Depression. Earlier this year, psilocybin was investigated as a means of assisting with TRD.

Clinical Trials 105

Clinical Trials Blood Pressure Treatment Therapy 105

Veriheal

MAY 30, 2023

But what if a safe and effective complementary plant-based treatment was widely available to alleviate cancer pain? of patients experience pain after curative treatment, while 66.4% in cancer patients undergoing anticancer treatment, 50.7% in those who had completed treatment, and as high as 66.7%

Medicine 98

Medicine Treatment Patients Data 98

Medicinal Genomics

FEBRUARY 8, 2024

We also know that there is a growing number of cannabis cultivators who are using remediation techniques (irradiation, ozone treatment, acid treatment, hydrogen peroxide treatment, etc.) These levels are orders of magnitude higher than the limit set by the Dutch Expert Committee on Occupational Safety (DECOS) : 90 EU/m^3.

Treatment 98

Treatment Dispensary Safety Conditions 98

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA has received adverse event reports involving delta-8 THC-containing products. brownies, gummies).

THC 105

THC Pets Events Hemp 105

The Cannigma

DECEMBER 19, 2021

It is often handled with preventive treatment based on drinking large amounts of water , eating a less acidic diet, reducing salt, and medications to help prevent stone formation. Bare said that when her daughter was 17 (she’s 22 today) she started integrating cannabis tinctures into her treatment regimen and that today she uses RSOs.

Treatment 135

Treatment Patients Dispensary Microdosing 135

CannaMD

JULY 2, 2020

To review Columbia Care’s COVID-19 delivery/pick-up and safety policies, please see: Florida Dispensaries: Coronavirus Policies. Curaleaf is offering two great sales events: Stock Up To Save Big : July 2 – July 3. On July 3, save an additional 10% in store if you wear red, white, and blue! 1/8th of Modern Flower GG4xSuper Skunk.

Safety 98

Safety Policy Marijuana Dispensary 98

Cannabis Law Report

DECEMBER 1, 2021

Ethics, Safety, and Abuse in Psychedelic Medicine. Vilmarie Fraguada Narloch, PsyD, is a licensed clinical psychologist in Chicago, Illinois, focusing on integrated treatment of co-occurring mental health and substance use disorders and psychedelic-assisted therapy. Wednesday, December 8th from 12:00-2:00pm PST. Do you love Chacruna?

Safety 52

Safety Medicine Therapy Research and Development 52

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

OCTOBER 21, 2021

Simon is not alone, one study reviewed online forum posts about cannabis and ADHD and found that 25% of posts indicated therapeutic benefits from this treatment – with statements like “While you are high … you will be able to focus much, much better than you normally would” and “(cannabis) helps me greatly with my ADHD.”

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

JULY 24, 2021

This expansive patent would allow Mydecine to scale its coverage in drug development research in lieu of promising discoveries and FDA-approval progress for novel therapeutics, including granting Breakthrough Therapy Designation to MDMA for the treatment of PTSD in recent years. About Mydecine Innovations Group.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. Diminishing efficacy of these receptors over time should be considered for proper treatment.

Events 48

Events THC Chronic Pain Sleep 48

MMJ Recs

JULY 11, 2024

Medical marijuana is a potential treatment for insomnia, and it offers an alternative to traditional pharmaceuticals. In this article, we explore the role of medical marijuana in addressing insomnia, examining its effectiveness, safety considerations, legal aspects, and practical considerations for patients and healthcare providers.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment. The Summit found that cannabis does not enhance athletic performance.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Puff Puff Post

MARCH 10, 2020

.” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. – Phase 2 Trial Underway.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JULY 14, 2021

The exploratory trial was the latest of several small trials where ImmunoFlex has focused on analysing immune system modulation at a genomic level resulting from treatment with compounds including CBD, THC, NAC and several other widely available compounds. Forward-looking statements are statements that relate to future, not past, events.

Research and Development 81

Research and Development Clinical Trials Events Treatment 81

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously. 9 -THC: 0.5mg, 1mg, or a placebo. ?

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. May not be reprinted without permission from the source. 2021.06.005.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

APRIL 19, 2020

As the coronavirus crisis continues, CannaMD remains committed to helping patients access treatment as safely as possible. Of the utmost importance, however, is the overall health and safety of our patients and Medtenders. Tune in all day tomorrow for a very special visual event on our Facebook and Instagram pages, @Rise.Cannabis.

Seed-To-Sale 94

Seed-To-Sale Marijuana Wellness and Beauty Patients 94

Cannabis Law Report

AUGUST 24, 2021

The Company has previously successfully completed a Phase 1 first-in-human safety and tolerability study for FSD-201 and the compound to be safe with no serious adverse side effects.

Clinical Trials 81

Clinical Trials Treatment Pharmaceutical Concentrates 81

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.

Clinical Trials 40

Clinical Trials Events Therapy Sleep 40

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Additionally, there were several instances in which cepharanthine displayed growth inhibition which was comparable or superior to current gold standard treatments, including colorectal, liver and skin cancers.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

The Joint Blog

APRIL 21, 2020

For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. ” “[M]ost studies reported no adverse events with acute administration and mild to moderate adverse effects with chronic administration.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. However, there is a growing realization that European health systems may not be prepared for these treatments. Psychedelic compounds – such as psilocybin and MDMA – are one such extremely promising area.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 23, 2021

Abernethy said, “We [FDA] remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety.”. How are CBD and other hemp-containing pet products being marketed today?

Pets 105

Pets Hemp CBD Food 105

The Joint Blog

JUNE 28, 2019

According to new research, the use of marijuana is a safe and effective treatment for those with fibromyalgia. The study, titled Safety and efficacy of medical cannabis in fibromyalgia, was published by the Journal of Clinical Medicine and was published online by the U.S. 0.72), concerns about cannabis treatment (OR 0.36, 95% C.I

Therapy 44

Therapy Chronic Pain Treatment Marijuana 44

NORML

MAY 24, 2019

At the same time, the bill would redirect tax revenue from a legal industry towards various programs that redress harms from the War on Drugs, while also increasing and improving public education and treatment programs geared towards responsible use, reducing overdoses, and saving lives.

Marijuana 105

Marijuana Education Advocacy Legislation 105

Illinois News Joint

APRIL 2, 2023

To find more cannabis-friendly events in Illinois, visit here. Below is Section 6z-112 of the State Finance Act that governs the distributions of the Cannabis Regulation Fund. For more Illinois cannabis industry news, visit here. For Illinois News Joint reviews, visit here.

Education 98

Education Cannabis Collective Programs 98

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health. ” Dosages of all CBM varied markedly.

Data 49

Data Treatment Marijuana Patients 49

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

TheAnswerPage

OCTOBER 6, 2021

months of treatment, with 60% of patients experiencing a treatment-related adverse event, 96% of which were mild or moderate. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA Netw Open. 2021;4(9):e2123930.

Sleep 40

Sleep Treatment Concentrates Safety 40